Telix Launches “Gallium Wave” Awareness Website

MELBOURNE, Australia & INDIANAPOLIS

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced the launch of a new website “Gallium Wave” (galliumwave.com), as part of the Company’s gallium awareness campaign.

The website illustrates how Telix, in partnership with suppliers, manufacturers and distributors, is paving a new path to increase future access to gallium-68 (⁶⁸Ga) based radiopharmaceuticals. Pharmacy-based generators and dose preparation can support the delivery of novel ⁶⁸Ga diagnostic radiopharmaceuticals “on demand”, delivering greater scheduling flexibility and control to the imaging practice.

Telix Chief Executive Officer Dr. Christian Behrenbruch noted, “The supply of ⁶⁸Ga-based radiopharmaceuticals will be a team effort, and our generator and cyclotron partners, as well as distribution partners like Cardinal Health, provide access to the technology needed to ensure greater reach and flexibility. We are excited to launch this educational resource to increase physician awareness of the reliability, flexibility and accessibility of ⁶⁸Ga.”

“Preparing the final ⁶⁸Ga radiopharmaceutical in the pharmacy versus manufacturing it simplifies the overall process. The pharmacy-prepared approach gives providers more flexibility in managing their business operations, as well as expanding patient access,” said Luke Augustine, Vice President of Business Development for Cardinal Health Nuclear & Precision Health Solutions. “This website is a much needed physician education resource in radioisotopes.”

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix’s lead investigational product, Illuccix^® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA,¹ and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA).² Telix is also progressing marketing authorisation applications for Illuccix^® in the European Union³ and Canada.⁴ None of Telix’s products have received a marketing authorisation in any jurisdiction.

¹ ASX disclosure 24/11/20.

² ASX disclosure 14/04/21.

³ ASX disclosure 1/05/20.

⁴ ASX disclosure 16/12/20.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210611005259/en/